Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

381
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
381
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

836
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
836
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

42
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
42
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

38
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
38
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

612
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
612
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.0K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

[Clinical spectrum, neuroimaging and therapeutic response to neurological syndromes associated with anti-GAD65].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Esophageal perforation: surgical outcomes in a referral center].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Loss of eyeball and periorbital tissues due to craniofacial trauma: Clinical case].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Elephantine Psoriasis. A case report].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Apendicitis aguda como complicación de la hernia de Garengeot: reporte de un caso].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

Bilateral Cataract Secondary to High-Voltage Electrical Burn: Case Report and Literature Review.

Revista medica del Instituto Mexicano del Seguro Social·2026

Related Experiment Video

Updated: Oct 29, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

102

[Hepatotoxicity probably associated with gabapentin].

Marisol Contreras-Mota1, Viviana Rosales-Cortés1

  • 1Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Departamento de Anestesiología. Ciudad de México, México.

Revista Medica Del Instituto Mexicano Del Seguro Social
|July 7, 2021
PubMed
Summary

Gabapentin, used for neuropathic pain, can rarely cause acute liver injury. This case report highlights that liver injury from gabapentin may resolve upon drug discontinuation.

Keywords:
Chemical and Drug Induced Liver InjuryGabapentinHepatotoxicityRenal Insufficiency, Chronic

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:31

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

76
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.9K

Related Experiment Videos

Last Updated: Oct 29, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

102
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:31

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

76
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.9K

Area of Science:

  • Pharmacology
  • Hepatology
  • Neurology

Background:

  • Gabapentin is a widely prescribed anticonvulsant medication.
  • It is frequently used as an adjuvant therapy for neuropathic pain management.
  • Hepatotoxicity is a rare but reported adverse effect of gabapentin.

Observation:

  • A 56-year-old male patient with chronic kidney disease on hemodialysis and spinal canal stenosis was treated with gabapentin.
  • The patient presented with acute liver injury.
  • The liver injury resolved after gabapentin was discontinued.

Findings:

  • The clinical presentation suggests gabapentin-induced acute liver injury.
  • Gabapentin undergoes minimal hepatic metabolism, making the exact mechanism of liver injury unclear.
  • Cessation of gabapentin led to the remission of hepatotoxicity.

Implications:

  • This case underscores the potential for gabapentin to cause liver injury, even in patients with comorbidities.
  • Healthcare providers should consider gabapentin as a potential cause of acute liver injury in susceptible patients.
  • Individualized patient assessment and cautious prescribing are essential when initiating gabapentin therapy.